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INTRODUCTION

Abstract—Although most current stroke intervention trials use
disability scales to determine outcome, little is known about the
sensitivity to change of these scales. The use of a more sensitive
measure would increase the statistical power of rehabilitation
treatment trials. We applied four well-known disability scales to
a group of stroke rehabilitation inpatients to compare sensitivity
to change. Ninety-five consecutive admissions to a stroke rehabilitation service were assessed for disability on admission and
discharge. Two global scales, the Modified Rankin Scale
(MRS) and the International Stroke Trial Measure (ISTM),
were compared with two activities of daily living (ADL) scales,
the Barthel Index (BI) and the Functional Independence Measure (FIM). We determined the number of patients that each
scale detected a clinically significant change in disability. Standardized response means (SRM) and receiver operating characteristic (ROC) analyses were performed. The MRS detected
change in 55 subjects, including all who changed on the ISTM;
the ISTM detected change in only 23 subjects. The BI detected
change in 71 subjects but demonstrated ceiling effects with 26%
of subjects scoring >95. The FIM was most sensitive, detecting
change in 91 subjects; no patient achieved a maximum score.
The SRM of the FIM was superior to that of the BI (2.18 versus
1.72), and ROC analysis revealed C-statistics of 0.82 for the BI,
0.59 for the MRS, and 0.51 for the ISTM. Global scales were
much less sensitive to changes in disability than were ADL
scales. Though ADL scales may take longer to administer, their
increased sensitivity may make them more useful in treatment
trials by allowing fewer subjects to be enrolled.

The advent of randomized controlled trials in rehabilitation has forced a critical examination of appropriate
end points. The recent success of the tissue plasminogen
activator (t-PA) trials in acute stroke has led to the expectation that rehabilitation trials will use the same trial end
points. Most current trials of early stroke interventions
use disability scales to assess outcome and determine
efficacy. Many scales are being used; most ongoing trials
use either the Modified Rankin Scale (MRS) or the Barthel Index (BI) or both [1,2]. A newer measure, specifically designed for intervention trials, was proposed for
use in the International Stroke Trial Measure (ISTM) that
examined the efficacy of aspirin or heparin administration [3]. Stroke investigators have chosen these measures
because of perceived high clinical utility, high interrater
reliability, and ease of use [4–11]. A fourth disability
scale, the Functional Independence Measure (FIM), is

Abbreviations: ADL = activities of daily living, BI = Barthel Index,
FIM = Functional Independence Measure, ICD = International Classifications of Diseases, ISTM = International Stroke Trial Measure,
MRS = Modified Rankin Scale, NINDS = National Institutes of Neurological Disorders and Stroke, ROC = receiver operating characteristic, SRM = standardized response means, t-PA = tissue plasminogen
activator, UK-TIA = United Kingdom transient ischemic attack.
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widely used in rehabilitation centers and has properties
useful for stroke investigators [12].
While much is known about the validity and interrater reliability of these four scales, less is known about
their capability to detect change in degree of disability.
Since the statistical power of a stroke trial is determined
in part by the responsiveness to change of the outcome
measure employed, a more sensitive measure allows efficacy to be tested with a smaller number of patients
[13,14]. Some have predicted that stroke patients will
someday be treated with a combination of different treatments [15,16], each with a variable but measurable
effect. If so, highly sensitive scales will be needed to
assess treatment efficacy. Thus, a better understanding of
the relative sensitivities of specific scales might lead to
improvements in stroke rehabilitation trial methodology
and facilitate the search for new treatments [14,17–21].
The scales examined in our study fall into two of the
categories described by Lyden and Lau, global scales and
activities of daily living (ADL) scales [18]. The MRS
and the ISTM are global scales that attempt to quickly
group patients into a few very large categories; any
change in category must therefore be clinically significant. This approach is intended to maximize interrater
reliability, if the borders of each category are well
defined. In addition to disability, the MRS and ISTM also
capture aspects of handicap, the social and economic
consequences of disease. Global scales do have weaknesses: the categories may be vague and no “correct”
answer can be objectively determined, scoring is determined by the overall impression of function, and the use
of large categories may reduce sensitivity to change.
ADL scales were designed to quantify the amounts of
assistance needed to perform specific tasks required for
independent living. After using the BI to quantify ADL
in stroke patients, Granger and coworkers developed the
FIM to address concerns about the BI’s lack of sensitivity
to change, ceiling effects, and inadequate assessment of
disability in patients with cognitive deficits [22,23]. ADL
scales should facilitate detection of smaller changes in
disability and for development of explicit scoring guidelines in which the correct answer can easily be determined. The disadvantages of this approach are that the
criterion for what constitutes “real” change may be
uncertain, that ADL scales have a more complex structure which may decrease interrater reliability, and that
they require more time to use.

In this study, we directly compare the sensitivity to
change of three scales used in acute stroke trials by studying patients during their stay on an inpatient rehabilitation
unit. To study sensitivity to change, we needed a group of
subjects likely to have changes in disability. A rehabilitation population is useful because the first few weeks after
stroke are a period of rapid clinical improvement and
because patients selected for rehabilitation are expected
to have a high likelihood of some improvement in disability during treatment [24]. We sought to determine the sensitivity to changes of scales currently used in early
intervention trials and to assess the impact on statistical
power in designing future rehabilitation treatment trials.

METHODS
Subjects
Consecutive admissions to an academic tertiary care
stroke rehabilitation service were included in this prospective study. All patients with ICD-9 (International
Classifications of Diseases) cerebrovascular disease
diagnoses were allowed, as were patients who also had
previous strokes. Patients were excluded from analysis if
their primary rehabilitation diagnosis was a condition
other than stroke, if data were incomplete, or if rehabilitation was discontinued because of medical or neurological complications. A multidisciplinary team cared for all
patients under the supervision of a single attending physician (AWD) during rehabilitation.
Measures
The global scales examined in the study are described
in the following:
• Modified Rankin Scale
– 0 = No symptoms.
– 1 = No significant disability despite symptoms;
able to perform all usual duties and activities.
– 2 = Slight disability; unable to perform all previous activities but able to look after own affairs
without assistance.
– 3 = Moderate disability; requiring some help,
but able to walk without assistance.
– 4 = Moderately severe disability; unable to walk
without assistance and unable to attend to own
bodily needs without assistance.
– 5 = Severe disability; bedridden, incontinent, and
requiring constant nursing care and attention.
– 6 = Dead.
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• International Stroke Trial Measure
– 1 = Alive and fully recovered from stroke.
– 2 = Alive and independent, but with residual
stroke symptoms.
– 3 = Alive, but dependent on others.
– 4 = Dead.
The ADL scales examined were as follows:
• Barthel Index. Items rated and weighting:
– 15 points = walking, transfers.
– 10 points = feeding, bowel, bladder, toileting,
dressing, stairs.
– 5 points = bathing, grooming.
• Functional Independence Measure. Eighteen items are
equally weighted; each is rated from 1 (completely
dependent) to 7 (independent without device). The
items included feeding, upper-limb dressing, lowerlimb dressing, bowel management, bladder management, feeding, bathing, walking, stairs, tub transfer,
toilet transfer, bed transfer, comprehension, expression, problem solving, social interaction, and memory.
The UK-TIA (United Kingdom transient ischemic
attack) version of the MRS was chosen because published interrater reliability data are available for this version [4,25]. A change of one point was deemed clinically
significant because the categories are broad and any
change detected would be expected to be large. The
ISTM was used as originally published [3]. As with the
MRS, any change detected on this scale was considered
clinically significant.
The original 100-point version of the BI was used;
the guidelines of Collin et al. were followed to clarify the
subjective portions of the BI [26]. The BI scores patients
on 10 ADL items in increments of five points; a 100-point
score indicates that the patient is independent in these
10 items. Following the most stringent recommendations
of Collin et al. [26], we chose a 20-point change as being
clinically significant. The modified BI of Shah et al. was
not included because it has not achieved wide use [27].
The FIM version 4.0 was used according to the standards of the Uniform Data System [28]. While no recommendations exist for what constitutes a clinically
significant change on the FIM, a 10-point improvement
decreases by almost 50 percent the time required to care
for a group of stroke patients in the community [29]. We
therefore chose this to be the threshold for change in this
study.

Procedures
The rehabilitation team generated FIM scores weekly
as part of the clinical routine; members of the team were
blinded to this investigation. All raters were trained to the
standards of the Uniform Data System for the FIM version 4.0 [28]. The BI scores were derived from the FIM
scores based on the scoring algorithm developed by
Nyein et al. [30].
The attending physician (AWD) assigned admission
and discharge ISTM and MRS scores by using procedures
currently in use for acute stroke trials [4]. He received
training in use of the MRS and ISTM as a coinvestigator
in several acute stroke trials. As part of this training, he
met study criteria for test-retest and interrater reliability
on these scales. He has also conducted such training on
the MRS and BI in eight multicenter stroke trials.
Admission and discharge ISTM and MRS scores
were assigned independently based on clinical evaluation
of the patient, chart reviews, and FIM scores. MRS
scores were assigned in accordance with current acute
stroke trial procedures [4].
ISTM scores were assigned as follows: Persons who
scored 5 or less on any item on the FIM were rated as a
3 and patients who scored 6 or greater on every FIM item
were rated as a 2. An ISTM score of 1 was reserved for
patients who scored 7 on all FIM items and whose discharge
neurologic exam indicated no stroke-related impairments or
return to prestroke neurologic status and functional status.
Each patient was then classified as to whether or not a clinically significant change (as defined in the following paragraph) occurred on each scale.
Analyses
Data were analyzed with SAS for Windows, version
6.10. Chi-square analyses using the Cochran-Mantel-Hanzel test were used for pair-wise comparisons of the baseline
and discharge scores of each scale. The effect size is a standardized estimate of the power of the test to detect change
[31]. The larger the coefficient is, the more responsive the
measure is. Standardized response means (SRM) were
computed for the FIM and BI as an index of effect size or
responsiveness. The SRM is equal to the mean change in
scores divided by the standard deviation of the change in
scores. The SRM cannot be calculated for ordinal scales
with few categories, and therefore this analysis was not performed for the MRS and ISTM. Logistic regression was
used to generate receiver operating characteristic (ROC)
analyses to evaluate the accuracy of the scales [32].
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RESULTS
Ninety-five subjects met entry criteria; all had a significant change on at least one of the scales used. There
were 53 women and 42 men. The mean interval from
stroke to rehabilitation admission was 9.0 + 6.4 days, and
the length of stay on the rehabilitation service was 19.5 +
8.3 days. The scores for one patient declined on the BI,
FIM, and MRS scales. Review of his chart indicated that
he suffered another stroke while on the rehabilitation service but was not transferred. Scores for this individual
were included in all analyses. Table 1 shows the mean
and median change scores for each scale. Since most
patients did not change on the ISTM, the median change
was zero.
The distribution of scores had relatively little shift
when patients were evaluated with the global scales, par-

ticularly the ISTM. The ADL scales demonstrated large
shifts of patients to higher functional levels. A ceiling
effect occurred with the use of the BI, since 25 patients
achieved either a 95 or 100; no patient achieved the highest possible score on the FIM. A modest floor effect was
also seen with use of the BI because many patients clustered at the lowest possible admission BI scores.
Table 2 shows the number of patients achieving clinically significant changes in one disability scale but not in
another. When we compare the global scales, the MRS
detected change in 33 patients who were unchanged when
measured with the ISTM (X 2 = 17.56, p < 0.001). All
patients who improved on the ISTM also improved when
measured by the MRS. Comparing the two ADL scales,
the FIM detected change in 18 patients that the BI did not
detect (X 2 = 9.33, p < 0.001). The three patients who

Table 1.
Change scores in study population (n = 95).

Mean Change*

Percent of Subjects
Changed† (%)

Median Change‡

MRS

—

47

1 level (0–2)

17 (18%)

0 (0%)

ISTM

—

24

0 level (0–1)

95 (100%)

0 (0%)

28 ± 16.2

100

30 points (0–70)

5 (5%)

26 (27%)

23.2 ± 10.6

100

22 points (4–55)

0 (0%)

0 (0%)

Measure

BI
FIM

are mean ± standard deviation.
Percent of subjects with a change of score.
‡Data are medians with ranges in parentheses.
BI = Barthel Index
*Data
†

Floor Effect,
Admission

Ceiling Effect,
Discharge

FIM = Functional Independence Measure
ISTM = International Stroke Trial Measure
MRS = Modified Rankin Scale

Table 2.
Subjects who achieved changes in disability status.*

Subjects Who DID Subjects Who DID Subjects Who DID Subjects Who DID
Change on MRS
Change on BI
Change on FIM
Change on ISTM
(n = 55)
(n = 71)
(n = 91)
(n = 23)
Subjects Who Did NOT Change on
MRS (n = 40)

—

25 (26%)

37 (39%)

0

Subjects Who Did NOT Change on BI
(n = 24)

5 (5%)

—

8 (19%)

4 (4%)

Subjects Who Did NOT Change on
FIM (n = 4)

1 (1%)

3 (3%)

—

0

Subjects Who Did NOT Change on
ISTM (n = 72)

33 (35%)

52 (55%)

70 (74%)

—

*See Results section of main paper for Chi-square analysis results.
BI = Barthel Index
FIM = Functional Independence Measure

ISTM = International Stroke Trial Measure
MRS = Modified Rankin Scale
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achieved clinically significant change on the BI but not
on the FIM had improvements on the same tasks on each
scale, but the FIM score changes were 1 or 2 points while
the corresponding BI changes were 5 or 10 points.
Comparisons between the global and ADL scales
were also informative. The BI detected change in 25 more
patients than the MRS (X 2 = 9.92, p < 0.002) and in
52 patients more than the ISTM. Chi-square analysis comparing the BI and the ISTM was not possible because of
the small numbers of subjects in some cells. However, the
BI once again displayed a ceiling effect: of the five
patients who changed on the MRS but not the BI, all
began rehabilitation with a BI score of 95 and thus could
not improve the 20 points required for a clinically significant change. Similarly, the ISTM detected a significant
change in four patients who did not achieve a clinically
significant change on the BI because of high initial BI
scores. The FIM detected change in a significantly larger
number of patients than the MRS (X 2 = 8.07, p < 0.005);
Chi-square analysis comparing the FIM and ISTM was
again impossible.
Standardized response means were calculated for the
BI and the FIM. The FIM (SRM = 2.18) was more
responsive than the BI (SRM = 1.72). The larger coefficient means that the FIM is more responsive to change
than the BI. These analyses cannot be performed on the
MRS and ISTM because they are ordinal scales.
Based on the Chi-square and effect size analyses, the
FIM was selected as the reference measure for the ROC
analysis. Sensitivity, specificity, and the area under the
ROC curves were computed for the BI, MRS, and ISTM.
The curves for each measure are presented in the Figure.
The BI has the highest predictive accuracy as indicated
graphically by the quick rise of the curve as well as by the
C-statistic (C = 0.82), which measures area under the
curve. The MRS and ISTM have curves that do not rise as
quickly; C-statistics for the MRS and ISTM are 0.59 and
0.51, respectively. The BI has higher sensitivity and specificity than the MRS and ISTM when compared to the FIM.

DISCUSSION
Disability scales are the current end points for acute
stroke treatment trials. Because some of these intervention trials (i.e., t-PA) have been successful in improving
outcome, stroke rehabilitation studies may be expected to
employ similar instruments. We report the relative sensi-

Figure.
ROC analysis. Sensitivity and specificity of BI, MRS, and ISTM
compared to FIM bibliography.

tivities to change of four disability scales in a stroke rehabilitation population to help investigators evaluate the
use of these measures in the postacute treatment setting.
We found large differences in the sensitivity to change
among the scales examined.
The criterion for “clinically significant” change chosen for each scale deserves comment. We followed the
advice of Adams to “avoid inflation of minimal changes
that are of dubious clinical significance” [17]. The choice
of a 1-point change on the 5-point MRS or the 4-point
ISTM is reasonable because inspection of the scales
reveals that the categories are quite large; any change
detected by these measures must be large and presumably
clinically significant. The absolute amount of change
defined as clinically significant for the ADL scales was
deliberately smaller than that chosen for the global scales,
thus exploiting a major strength of the ADL scales. Nonetheless, we believe the levels we set for the two ADL
scales detect a change clearly meaningful to the patient,
family, and clinician. Literature has had little explicit
comment about what constitutes a “real” change in the BI.
Wade et. al. and Shah both suggest that a 20-point threshold would certainly indicate important change [5,27].
This criterion may be overly rigorous; even so, the BI
detected change in a much larger proportion of patients
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that the MRS. For the purposes of a treatment trial, a
smaller difference between the treatment and control
groups on the BI might be adequate.
There are few published comparisons of the FIM and
BI in stroke rehabilitation populations. The FIM evolved
from the BI and was intended to address concerns about
the BI, including lack of sensitivity to change, ceiling
effects, and inadequate assessment of disability in
patients with primarily cognitive deficits. Our data
clearly demonstrate that the FIM is more responsive to
change and less prone to ceiling effects than the BI. A 10point change in a FIM score requires net improvement of
one level or more in many items. Based on a recent study
[29], a 10-point FIM score improvement would reduce by
nearly 50 percent the average amount of time required to
physically care for this cohort of patients in the home, a
change which patient and family would surely consider
significant.
Although the ceiling effect of the BI is well known,
the magnitude of the effect in our study was unexpected.
Twenty percent of our subjects achieved the maximum
95 or 100 score on the BI, while no patient achieved the
maximum score on the FIM. Thus, the BI classified some
of our patients as “normal” when they continued to have
measurable disability when evaluated with the FIM. A
floor effect for the BI was also present, suggesting that
the BI would also fail to detect differences in the most
severely affected population. Our findings differ from
those reported by van der Putten et al [33], who reported
no significant floor or ceiling effects for either the BI or
FIM; the differences observed in our study may be
related to the differences between United States and
United Kingdom rehabilitation settings.
Can results obtained with our patients be generalized
to the cohort of patients used in all acute and postacute
stroke trials? The population used in our study was not a
random sample of all stroke patients or was it those who
necessarily represent the population that would be
enrolled in all intervention trials. By the nature of a rehabilitation service, those patients with immediate and
complete recovery after stroke are excluded, as are those
who die or who are severely disabled. Our patients were
mostly made up of the moderately disabled, the “middle
band” of stroke patients [24]. Since most stroke intervention trials also attempt to target this group by excluding
mildly and severely affected subjects, we argue that our
cohort is actually enriched in the population of greatest
interest to investigators. For example, in the National

Institutes of Neurological Disorders and Stroke (NINDS)
t-PA trial [34], 66 percent of survivors in the placebo arm
scored between 2 and 5 on the MRS and would potentially be included in our study population.
Our data support the use of ADL scales over the use of
global scales in all stroke intervention trials. The use of
common measures would allow comparisons across the full
spectrum of treatment strategies, including rehabilitation.
This will be particularly helpful in cost-benefit analyses
that compare pharmaceutical treatments with behavioral
interventions. If early and late treatments are combined, a
common end point will be necessary. Those who select a
global scale may be sacrificing the ability to detect change
in disability on the assumption that they will be compensated by very high interrater reliability. While there are
studies reporting adequate interrater reliability of the MRS
in tightly controlled circumstances, we are not aware of a
study that directly compares the interrater reliability of the
BI, the ISTM, and the MRS under conditions that realistically simulate a multicenter trial. One study (using stroke
research nurses who worked together at a single center)
actually found the BI to have better interrater reliability
than the MRS [6].
When an ADL scale as an efficacy measure in stroke
trials is chosen, the FIM appears to be methodologically
superior to the BI, at least in U.S. stroke rehabilitation
settings. The FIM detected change in more patients than
the BI and did not exhibit the ceiling and floor effects
seen in the BI. While the FIM is more complex and takes
longer to learn and administer, it is designed for use by
nonphysicians. The small additional cost of a therapist’s
time may be offset by the need to enroll fewer patients
when using a more sensitive measure. Scoring of the FIM
via telephone interview is used widely and can greatly
reduce the cost of collecting outcome data [25].
Our results must be evaluated in the context of the
recent NINDS t-PA trial in which subjects were classified
into “favorable” and “unfavorable” outcome groups [34].
First, creation of a dichotomous outcome measure may be
appropriate for evaluating a thrombolytic agent where the
effect of treatment is expected to be either quite dramatic
or nonexistent. This approach may not be optimal for
other classes of agents in which the treatment effect may
be less dramatic [14]. Incremental improvement or worsening in function may be missed by an unresponsive outcome measure, and agents may not be correctly evaluated
for efficacy or safety. Second, using dichotomous outcome measures may increase the importance of the ceiling
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effects present in currently used outcome measures.
Unwary clinicians or health care planners may interpret
“favorable” to mean “cured.” The false classification of
patients as “cured” based on a measure with a large ceiling effect, such as the BI, may overstate the effect of a
treatment.

CONCLUSION
In summary, for this moderately disabled stroke population, we found wide variations in the sensitivity to
change in three disability measures currently used in
stroke intervention trials and one disability measure
widely used in rehabilitation centers. We emphasize that
sensitivity to change is only one factor in choosing a disability scale and that reliability, validity, specificity, and
practicality also must be considered. Further direct comparison of the properties of disability scales may be useful
in optimizing stroke trial design.
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